Veru Inc. (NASDAQ:VERU) Sees Significant Growth in Short Interest

Veru Inc. (NASDAQ:VERU) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 735,150 shares, a growth of 19.2% from the December 31st total of 616,770 shares. Approximately 5.4% of the company’s shares are short sold. Based on an average daily trading volume, of 127,880 shares, the days-to-cover ratio is presently 5.7 days. Based on an average daily trading volume, of 127,880 shares, the days-to-cover ratio is presently 5.7 days. Approximately 5.4% of the company’s shares are short sold.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wall Street Zen cut Veru from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer reiterated an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group started coverage on shares of Veru in a report on Thursday, December 18th. They set a “buy” rating and a $25.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Veru presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Veru Price Performance

VERU stock opened at $2.57 on Tuesday. The stock has a market capitalization of $41.25 million, a P/E ratio of -1.17 and a beta of -1.42. Veru has a fifty-two week low of $2.10 and a fifty-two week high of $7.40. The business has a 50-day moving average of $2.43 and a 200-day moving average of $3.25.

Veru (NASDAQ:VERU) last released its earnings results on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same period in the prior year, the firm posted ($0.28) earnings per share. Equities analysts expect that Veru will post -0.22 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. increased its stake in Veru by 3.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 197,876 shares of the company’s stock valued at $423,000 after buying an additional 5,708 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Veru by 5.5% in the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after acquiring an additional 9,637 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Veru in the third quarter valued at about $38,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Veru in the third quarter valued at about $47,000. Finally, 180 Wealth Advisors LLC raised its holdings in Veru by 5.9% during the second quarter. 180 Wealth Advisors LLC now owns 458,887 shares of the company’s stock worth $267,000 after acquiring an additional 25,554 shares in the last quarter. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.